Approvals

  1. Erleada (apalutamide) gets positive opinion from the EMA

    New medicine shows statistically significant improvements for prostate cancer patients.

    backlit man on mountain arms out

    Read more »
  2. Orkambi approved in Australia, will others follow?

    Australia provides reimbursement for cystic fibrosis medicine.

    family blowing bubbles

    Read more »
  3. Alunbrig (brigatinib) approved in Europe for another type of lung cancer

    The European Commission has approved Alunbrig (brigatinib) for the treatment of a specific type of lung cancer.

    eu stars

    Read more »
  4. Newly approved in the EU: Durvalumab (Imfinzi) an immunotherapy for Stage III Lung Cancer

    Read more »
  5. CAR T cell approval may offer patients a new form of therapy

    Industry NewsAccording to study investigators, about a third of patients could benefit from this therapy that may offer remissions, relieve symptoms and save lives.

    Read more »
  6. 2018 - Good year for new FDA approvals of cancer treatments

    2018 has been a good year for new cancer treatments says the U.S. AACR. 
    AACR news 

    Read more »
  7. Kisqali (ribociclib) approved for additional indications in HR+/HER2- advanced breast cancer

    News updateKisqali is now the only CDK4/6 inhibitor for use with an aromatase inhibitor for the treatment of pre-, peri- or postmenopausal women in the US.

    Read more »
  8. In-depth review of the new EMA-approved preventative migraine injection

    The approval marks a significant advance in the field of neurology — and one that migraine patients will no doubt welcome.

    News update


    Read more »
  9. Erenumab (Aimovig) now approved for the European Union

    The new preventive medicine for migraine Aimovig (erenumab) has been approved by the EMA. Read more...
    Breaking News 

    Read more »
  10. FDA grants accelerated approval to the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) for metastatic colorectal cancer

    Industry News

    Read more »
  11. Array BioPharma Announces FDA Approval of Braftovi (encorafenib) in Combination with Mektovi (binimetinib) for Unresectable or Metastatic Melanoma with BRAF Mutations

    Industry News

    Read more »
  12. Full marketing authorisation for blinatumomab

    Industry NewsThe latest approval renders the previous 'temporary approval' a full approval, without further results needed.

    Read more »